Drug Trial Radar · NCT04143061
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa
Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,328
Actual
Start
Dec 30, 2019
Primary completion
Jan 28, 2023
Study completion Jan 28, 2023
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be a Phase III, modified double-blind (open-label for toddlers in India), randomized, parallel-group, active-controlled, step-wise, multi-center study to compare and describe the immunogenicity and safety of MenACYW conjugate vaccine when administered as a single dose in healthy adults, adolescents, children, and toddlers in India and a modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare and describe the immunogenicity and safety of MenACYW conjugate vaccine when administered as a single dose in healthy adolescents and children in RSA.
Conditions
- Meningococcal Immunization
- Healthy Volunteers
Interventions
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccineBiological
Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccineBiological
Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccineBiological
Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Group 5 + 7 and Group 6 + 8: Percentage of Participants Who Achieved Antibody Titers ≥1:8 Against Meningococcal Serogroups A, C, Y, and WTime frame: Day 30 (30 days post-vaccination on Day 0)
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site Number : 3560002
Bangalore, India
Investigational Site Number : 3560016
Belagavi, India
Investigational Site Number : 3560007
Chennai, India
Investigational Site Number : 3560004
Hyderabad, India
Investigational Site Number : 3560011
Kolkata, India
Investigational Site Number : 3560012
Mysore, India
Investigational Site Number : 3560015
Odisha, India
Investigational Site Number : 3560003
Pune, India
Investigational Site Number : 3560008
Pune, India
Investigational Site Number : 3560010
Punjab, India
Investigational Site Number : 7100004
Bertsham, South Africa
Investigational Site Number : 7100007
Bloemfontein, South Africa
Investigational Site Number : 7100005
Cape Town, South Africa
Investigational Site Number : 7100002
Cape Town, South Africa
Investigational Site Number : 7100001
Middelburg, South Africa
Investigational Site Number : 7100006
Pretoria, South Africa
Investigational Site Number : 7100003
Soweto, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.